HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caramori, M. L. Articles by Gross, J. L. Search for Related Content PubMed PubMed Citation Articles by Caramori, M. L. Articles by Gross, J. L. Social Bookmarking                What's this?

The Human Peroxisome Proliferator-Activated Receptor 2 (PPAR2) Pro12Ala Polymorphism Is Associated With Decreased Risk of Diabetic Nephropathy in Patients With Type 2 Diabetes

From the Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

The peroxisome proliferator-activated receptor 2 (PPAR2) Pro12Ala polymorphism has been associated with a decreased risk of type 2 diabetes and a lower albumin excretion rate (AER) in patients with established diabetes. We performed a case-control study aiming to evaluate the association between the Pro12Ala polymorphism and diabetic nephropathy. Genomic DNA was obtained from 104 type 2 diabetic patients (case subjects) with chronic renal insufficiency (78 on dialysis and 26 with proteinuria [AER 200 µg/min] and serum creatinine 2.0 mg/dl) and 212 normoalbuminuric patients (AER <20 µg/min) with known diabetes duration 10 years (control subjects). The genotypic distribution of the PPAR2 Pro12Ala polymorphism in these diabetic patients was in Hardy-Weinberg equilibrium, and the Ala allele frequency was 9%. The frequency of Ala carriers (Ala/Ala or Ala/Pro) was 20.3% in control subjects and 10.6% in case subjects (P = 0.031). The odds ratio of having diabetic nephropathy for Ala carriers was 0.465 (95% CI 0.229–0.945; P = 0.034). Carriers of the Ala allele were not different from noncarriers (Pro/Pro) regarding sex (38.9 vs. 44.1% males) or ethnicity (77.4 vs. 71.7% white) distribution, age (61 ± 10 vs. 61 ± 10 years), known diabetes duration (17 ± 7 vs. 16 ± 7 years), BMI (27 ± 4 vs. 28 ± 5 kg/m²), fasting plasma glucose (184 ± 81 vs. 176 ± 72 mg/dl), HbA_1c (6.7 ± 2.3 vs. 6.9 ± 2.4%; high-performance liquid chromatography reference range: 2.7–4.3%), and systolic (145 ± 27 vs. 0.144 ± 24 mmHg) or diastolic (87 ± 14 vs. 85 ± 14 mmHg) blood pressure, respectively. In conclusion, the presence of the Ala allele may confer protection from diabetic nephropathy in patients with type 2 diabetes.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. G. Ewens, R. A. George, K. Sharma, F. N. Ziyadeh, and R. S. Spielman Assessment of 115 Candidate Genes for Diabetic Nephropathy by Transmission/Disequilibrium Test Diabetes, November 1, 2005; 54(11): 3305 - 3318. [Abstract] [Full Text] [PDF]

				S. De Cosmo, A. Marucci, E. Ciociola, R. Di Paola, L. Pucci, G. Penno, S. Del Prato, G. P. Piras, R. Trevisan, S. Giunti, et al. Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2419 - 2420. [Full Text] [PDF]

				J. C. Florez Phenotypic Consequences of the Peroxisome Proliferator-Activated Receptor-{gamma} Pro12Ala Polymorphism: The Weight of the Evidence in Genetic Association Studies J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4234 - 4237. [Full Text] [PDF]